Our case supports the hypothesis that interfering with the IL-17 signalling pathway might be a promising option for the maintenance of glucocorticoid-free remission in GCA and that ixekizumab might be a valid alternative to secukinumab in GCA. Here, IL17A is linked to temporal arteritis.